+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of acute myeloid leukemia: state-of-the-art and future directions

Treatment of acute myeloid leukemia: state-of-the-art and future directions

Seminars in Hematology 39(3 Suppl 2): 4-10

Despite major recent advances in the understanding of the molecular biology of the disease, the treatment of acute myeloid leukemia (AML) in adults remains challenging. For the 75% of AML patients older than 60 years, currently available treatments produce significant toxicity with poor overall response rates and survival. In younger patients, standard regimens using cytarabine and an anthracycline for induction followed by some form of intensive postremission therapy can produce response rates of 70% with 5-year relapse-free survival rates of 25% to 40%. Chromosomal analyses define three prognostic categories with favorable, intermediate, and unfavorable risk. In older adults, AML appears to be an intrinsically resistant disorder of proximal pluripotent hematopoietic stem cells. A variety of targeted therapies currently in development include modulators of MDR1-mediated drug resistance, immunotherapeutics, angiogenesis inhibitors, proapoptotic antisense oligonucleotides, and specific small molecule inhibitors of tyrosine kinase and farnesyltransferase. For example, oral farnesyltransferase inhibitors have demonstrated activity and tolerability in patients with refractory AML and are now in phase II testing. Such targeted therapeutics offer the promise of novel antileukemic activity combined with an improved therapeutic index.

(PDF same-day service: $19.90)

Accession: 035980795

Download citation: RISBibTeXText

PMID: 12214287

DOI: 10.1053/shem.2002.35977

Related references

Induction and postremission strategies in acute myeloid leukemia: state of the art and future directions. Hematology/Oncology Clinics of North America 25(6): 1189-1213, 2012

Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions. World Journal of Stem Cells 6(2): 69-81, 2014

Older Patients With Acute Myeloid Leukemia: Treatment Challenges and Future Directions. Ochsner Journal 17(4): 398-404, 2017

Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions. Seminars in Hematology 52(3): 172-183, 2015

Acute myeloid leukemia in children: Current status and future directions. Pediatrics International 58(2): 71-80, 2015

Antibody therapy in acute myeloid leukemia: current status and future directions. Clinical Lymphoma 2 Suppl 1: S12-S18, 2002

FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions. Molecular Cancer Therapeutics 16(6): 991-1001, 2017

Measuring quality of life in acute myeloid leukemia: limitations and future directions. Expert Review of Hematology 9(9): 821-823, 2016

Immune evasion in acute myeloid leukemia: current concepts and future directions. Journal for ImmunoTherapy of Cancer 1(13): -, 2013

Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia: Challenges and Future Directions. Journal of Molecular Diagnostics, 2018

Management of Newly Diagnosed Acute Myeloid Leukemia in the Elderly: Current Strategies and Future Directions. Drugs & Aging 32(12): 983-997, 2016

Regulation of c-fos gene transcription and myeloid cell differentiation by acute myeloid leukemia 1 and acute myeloid leukemia-MTG8, a chimeric leukemogenic derivative of acute myeloid leukemia 1. FEBS Letters 446(1): 86-90, March 5, 1999

Acute myelogenous leukemia current treatment and future directions. American Journal of Medicine 92(3): 286-295, 1992

The treatment of acute myeloid leukemia: past, present, and future. Japanese Journal of Clinical Hematology 45(12): 1223-1232, 2005

Improved treatment results in Mexican children with acute myeloid leukemia using a Medical Research Council (MRC)-acute myeloid leukemia 10 modified protocol. Leukemia & Lymphoma 50(7): 1132-1137, 2009